Skip to Content

Fluzone Quadrivalent Approval History

FDA Approved: Yes (First approved June 7, 2013)
Brand name: Fluzone Quadrivalent
Generic name: influenza virus vaccine, inactivated
Dosage form: Suspension for Intramuscular Injection
Company: Sanofi
Treatment for: Influenza Prophylaxis

Fluzone Quadrivalent is an inactivated influenza virus vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

Development History and FDA Approval Process for Fluzone Quadrivalent

Nov  4, 2019Approval FDA Approves Fluzone High-Dose Quadrivalent (Influenza Vaccine) for Adults 65 Years of Age and Older
Jan 23, 2019Approval FDA Approves Use of 0.5 mL Dose of Fluzone Quadrivalent (influenza vaccine) in Children as Young as 6 Months of Age
Dec 12, 2014Approval Sanofi Pasteur Announces FDA Approval Of Fluzone Intradermal Quadrivalent
Jun 11, 2013Approval New Fluzone Quadrivalent Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults
May 10, 2011Approval FDA Licenses Fluzone Intradermal - Sanofi Pasteur's New Influenza Vaccine Delivered by Intradermal Microinjection
Dec 23, 2009Approval FDA Approves a High Dose Seasonal Influenza Vaccine Specifically Intended for People Ages 65 and Older

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.